Topotecan Hydrochloride

盐酸托泊替康

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug NameTopotecan Hydrochloride
Drug Alias NameNogitecan Hydrochloride拓普替康Topotecanum拓泊替康盐酸拓扑替康 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursCentral Nervous System Lymphoma +[46] 
Global Approved IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[4] 
Approved Indications in ChinaOvarian Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date1996/05/28
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcPeking Union Medical College HospitalSandoz Pharmaceuticals Dd +[8] 
Inactive CompaniesWeill Medical College of Cornell UniversitySmithkline BeechamMasonic Cancer Center, University Of Minnesota +[10] 
Active IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsCNS Embryonal TumorSolid tumoursCentral Nervous System Lymphoma +[40] 

Other Information

ATC CodeL01CE01
Related LinksWikipediaDrugBankKEGG